Local developer brings biotechnology company to Lincoln Park medical research facility

Sterling Bay, Chicago’s premiere real estate investment and development firm, and its life sciences division, The Labs, today announced that Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs, will be its first tenant at 2430 N Halsted, a recently redeveloped, 120,000-square- foot, state-of-the-art medical research lab. Located in the heart of the City’s Lincoln Park neighborhood, 2430 N Halsted features fully integrated wet lab space ideal for both emerging and established life science companies.

Exicure is currently headquartered in the Illinois Science + Technology Park with an additional location in Cambridge, Massachusetts, but will move its research and headquarters operation into The Labs at 2430 N Halsted. The clinical stage biotechnology company will occupy approximately 30,000 square feet at the five- story Lincoln Park facility.
“Exicure’s expansion in Lincoln Park is just the beginning of Sterling Bay’s investment in redeveloping high- quality lab space in one of Chicago’s most conveniently located downtown neighborhoods,” said Andy Gloor, CEO at Sterling Bay. “As we continue to acquire and develop best-in-class research facilities, including those to come at Lincoln Yards, we will serve the life science sector growing in Chicago, further cementing the City’s reputation as a hub for cutting edge biomedical innovation.”
For many life science startups that begin in the labs of Chicago’s most prestigious biomedical research universities, the availability of high-quality, affordable wet lab space is a welcome development that will be embraced by the technology commercialization community.

“Chicago has a deep talent pool and access to world-class universities. Exicure has been partnering with pharmaceutical companies to bring our genetic medicines into clinical trials, and we are thrilled to have incredible facilities to match our growth. With our expansion, we can continue as part of the vibrant Chicago biotech community”, added Exicure CEO Dr. David Giljohann.
Sterling Bay will continue to partner with local research, medical and educational institutions at 2430 N Halsted, as well as at Lincoln Yards, to explore new opportunities for expanding Chicago’s reputation as a global leader in medical innovation through increased access to best-in-class research lab facilities.

Sterling Bay is a Chicago-based real estate investment and development company with expertise spanning all aspects of real estate ownership. Known for creating world-class urban campuses for companies such as Google, McDonald’s, WPP, Pinterest, Dyson and Tyson Foods, Sterling Bay is consistently recognized for award-winning projects that transform space, enhance communities and strengthen a company’s culture and brand. Sterling Bay’s team of more than 200 professionals is responsible for a portfolio exceeding $5 billion, and a development pipeline of more than $9 billion. For more information, visit www.sterlingbay.com.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure’s lead program is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge,  MA.